INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 51 filers reported holding INOZYME PHARMA INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,878,374 | -7.4% | 4,494,851 | +22.8% | 7.53% | +12.0% |
| Q2 2023 | $20,394,655 | +10.8% | 3,661,518 | +13.9% | 6.72% | -11.3% |
| Q1 2023 | $18,413,848 | +559.0% | 3,213,586 | +20.8% | 7.58% | +524.0% |
| Q4 2022 | $2,794,212 | -60.8% | 2,661,154 | 0.0% | 1.22% | -53.4% |
| Q3 2022 | $7,132,000 | -43.8% | 2,661,154 | 0.0% | 2.61% | -59.2% |
| Q2 2022 | $12,694,000 | +95.1% | 2,661,154 | +67.2% | 6.40% | +107.7% |
| Q1 2022 | $6,508,000 | -40.0% | 1,591,154 | 0.0% | 3.08% | -32.2% |
| Q4 2021 | $10,852,000 | -41.2% | 1,591,154 | 0.0% | 4.54% | -30.4% |
| Q3 2021 | $18,441,000 | -32.0% | 1,591,154 | 0.0% | 6.52% | -39.0% |
| Q2 2021 | $27,113,000 | -13.9% | 1,591,154 | 0.0% | 10.69% | +5.7% |
| Q1 2021 | $31,505,000 | -4.1% | 1,591,154 | 0.0% | 10.11% | -6.6% |
| Q4 2020 | $32,841,000 | – | 1,591,154 | – | 10.83% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $18,441,000 | 6.52% |
| CHI Advisors LLC | 920,264 | $10,666,000 | 3.11% |
| Sofinnova Investments, Inc. | 2,028,308 | $23,508,000 | 1.39% |
| MPM BioImpact LLC | 320,724 | $3,717,000 | 0.58% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,344,786 | $27,176,000 | 0.53% |
| NEA Management Company, LLC | 2,444,379 | $28,330,000 | 0.34% |
| Rock Springs Capital Management LP | 850,015 | $9,852,000 | 0.21% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 986,400 | $11,432,000 | 0.19% |
| Overbrook Management Corp | 16,726 | $194,000 | 0.04% |
| Orbimed Advisors | 294,000 | $3,407,000 | 0.04% |